Skip to content

Study · Observational study · 2008

2 results

Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism.

Kageyama K, Nigawara T, Sakihara S, Takayasu S, Terui K, Moriyama T, Suda T

Endocrine journal21 May 2008Cited by 17 (Europe PMC)

PMID18493103 (opens in a new tab)DOI10.1507/endocrj.k07e-168 (opens in a new tab)PepBankPUB-18493103
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyOther

    In patients with hypopituitarism, those with a significant ACTH response to the insulin tolerance test also had a significant ACTH response to the GHRP‑2 test.

    In plain wordsIn patients with pituitary disease, people who responded to the standard insulin test also responded to the GHRP‑2 test.

    Peptide
    GHRP-2
    Outcome
    Not applicableACTH response to GHRP-2 test in patients with significant ACTH response to ITT
    Study

    n: not reported in source

    Comparator
    Insulin tolerance test
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We showed that patients with significant ACTH response to ITT also had significant response to the GHRP-2 test, while patients with no significant ACTH response to ITT also had no significant response to the GHRP-2 test.
    1 context sentence
    Summary · context
    In the present study, we examined the diagnostic usefulness of the GHRP-2 test as a substitute for ITT in hypopituitarism.
  2. 02HumanObservational studyOther

    In patients with hypopituitarism, those with no significant ACTH response to the insulin tolerance test also had no significant response to the GHRP‑2 test.

    In plain wordsIn patients with pituitary disease, people who did not respond to the standard insulin test also did not respond to the GHRP‑2 test.

    Peptide
    GHRP-2
    Outcome
    Not applicableACTH response to GHRP-2 test in patients with no significant ACTH response to ITT
    Study

    n: not reported in source

    Comparator
    Insulin tolerance test
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We showed that patients with significant ACTH response to ITT also had significant response to the GHRP-2 test, while patients with no significant ACTH response to ITT also had no significant response to the GHRP-2 test.
    1 context sentence
    Summary · context
    In the present study, we examined the diagnostic usefulness of the GHRP-2 test as a substitute for ITT in hypopituitarism.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.